The Myth of a COVID-19 Vaccine to the Rescue

Aided by establishment media fear-mongering, the public mind is being manipulated to support COVID-19 mass vaxxing as a way to protect against coronavirus infections.

Unmentioned is that all vaccines are toxic and hazardous to human health.

Taking them risks contracting the disease they’re supposed to protect against, along with developing other serious diseases later in life.

In other words, the promoted cure can be worse than the disease.

Rushing development of COVID-19 vaccines for mass vaxxing amounts to playing Russian roulette with human health.

Instead of warning the public of the dangers, establishment media are complicit in ignoring them.

On Tuesday, the NYT touted limited phase one tests of biotech company Moderna’s experimental COVID-19 vaccine, claiming results showed it was “safe and provoked a strong immune response.”

Eight test subjects were vaxxed, given two low doses in a test for “safety.”

Ignored by the Times and other media reports were potential longer-term adverse reactions and known hazards of all vaccines. Little is learned about experimental ones based on short-term results with a handful of subjects.

News about Moderna’s drug sent its stock price soaring about 25% on Monday.

After the market closed, the company announced a $1.25 billion public offering of its common shares. Their valuation slumped in after-hours trading.

Reportedly its CEO Stephane Bancel has been dumping large numbers of shares.

Moderna’s largest shareholder Flagship Pioneer has been doing the same thing — cashing in while the stock is hot, notably before it may cool down or crash if later experimental vaccine tests show negative results.

The Times also promoted the false promise of a “return to normal” ahead, claiming Monday’s strong market rally reflected the “prospect,” adding:

“Vaccines are now seen as the best and perhaps only hope of stopping or even slowing” COVID-19 outbreaks and deaths.

Monday’s rally was more about market manipulation than the prospect of restoration of economic health.

On the same day, Tass reported over “93,000 confirmed” COVID-19 cases worldwide in the last 24 hours, around 4,500 more deaths — showing no letup in the global public health problem.

Are vaccines to the rescue the solution? Despite years of research, no successful coronavirus vaccines were ever developed.

Is it likely that a never before achieved breakthrough will change things by yearend?

Is a miracle vaccine coming in the months ahead?

Weeks earlier, Nature magazine and other scientific journals explained warnings by researchers that rushing COVID-19 vaccine development for widespread use in the coming months could increase the risk of infection rather than protect against it.

Earlier research on coronavirus vaccines showed they risk vaccine enhancement, worsening infection if gotten, not protecting vaxxed individuals.

How this happens is yet to be understood. It’s a major stumbling block to developing coronavirus vaccines — what may never be achieved, notably because the virus mutates into many new forms, each different from others in characteristics.

On Tuesday, Thailand Medical News (TMN) reported that University of Hong Kong researchers found the following:

“(A)lthough individuals infected with either severe acute respiratory syndrome coronavirus (SARS-CoV) or SARS-CoV-2 (that causes COVID-19) produce antibodies that bind to the other coronavirus, the cross-reactive antibodies are not cross protective, at least in cell-culture experiments.”

It suggests that developing coronavirus vaccines may not be possible — at least not unless or until there are research breakthroughs never achieved before.

According to Hong Kong University researcher Dr. Chris Mok:

“Since coronavirus outbreaks are likely to continue to pose global health risks in the future, the possibility of developing a cross-protective vaccine against multiple coronaviruses has been considered.”

“Our findings, albeit limited at present, would suggest that broadly cross-neutralizing antibodies to coronaviruses might not be commonly produced by the human immune repertoire.”

“Moving forward, monoclonal antibody discovery and characterization will be crucial to the development of a SARS-CoV-2 vaccine in the short-term, as well as a cross-protective coronavirus vaccine in the long term.”

No breakthroughs exist toward achieving these objectives — nor in developing a miracle COVID-19 cure.

The virus is likely to be around for a long time, maybe forever like season flu that results in millions of infections, hundreds of thousands of hospitalizations, and tens of thousands of deaths in the US annually.

It’s a forever epidemic and pandemic — unaccompanied by establishment media fear-mongering headlines, despite the global harm to countless millions annually like clockwork.


Note to readers: please click the share buttons below. Forward this article to your email lists. Crosspost on your blog site, internet forums. etc.

Award-winning author Stephen Lendman lives in Chicago. He can be reached at [email protected]. He is a Research Associate of the Centre for Research on Globalization (CRG)

His new book as editor and contributor is titled “Flashpoint in Ukraine: US Drive for Hegemony Risks WW III.”

Visit his blog site at

Comment on Global Research Articles on our Facebook page

Become a Member of Global Research

Articles by: Stephen Lendman

About the author:

Stephen Lendman lives in Chicago. He can be reached at [email protected] His new book as editor and contributor is titled "Flashpoint in Ukraine: US Drive for Hegemony Risks WW III." Visit his blog site at Listen to cutting-edge discussions with distinguished guests on the Progressive Radio News Hour on the Progressive Radio Network. It airs three times weekly: live on Sundays at 1PM Central time plus two prerecorded archived programs.

Disclaimer: The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: [email protected] contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: [email protected]